SNIPERs

SNIPER(ABL)-062, in which an ABL inhibitor is linked to a ligand of cIAP1 via a linker containing a variable polyethylene glycol (PEG) unit, shows a potent activity to degrade the BCR-ABL protein.

SNIPER(BRD4)-1 is a specific and nongenetic inhibitor of apoptosis protein (IAP)-dependent protein eraser (SNIPER) which acts as a protein degradation inducer of bromodomain-containing protein 4 (BRD4).

SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 10 nM. IC50s are 0.54 nM, 10 nM, 12 nM, and 50 nM for ABL, cIAP1, cIAP2, XIAP, respectively.

SNIPER(ABL)-033, conjugating HG-7-85-01 (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 0.3 μM.

SNIPER(ABL)-024, conjugating GNF5 (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 5μM.

SNIPER(ABL)-058, conjugating Imatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 10 μM.

SNIPER(CRABP)-11, also known as PROTAC cIAP1 degrader-4, is a potent protein degrader.

HG-7-85-01-NH2 is a synthetic ligand designed for use in SNIPER (specific and potent target protein degradation) applications. This compound features the HG-7-85-01 moiety, which inhibits ABL, and is linked to an IAP ligand to facilitate targeted protein degradation. It holds potential for advancing research in targeted therapies and cellular protein regulation.

BzNH-BS is a bifunctional reagent designed to target the cellular inhibitor of apoptosis protein 1 (cIAP1) through its ligand methyl-bestatin (MeBS) and a benzoyl-amide. This compound operates as a SNIPER (Specific and Non-genetic IAP-dependent protein Eraser) to promote the ubiquitination and subsequent degradation of cIAP1. BzNH-BS is useful in studying apoptosis regulation and can be applied in cancer research to explore IAP-related pathways and therapeutic interventions.